Literature DB >> 35919032

Association of the Interleukin-10-592C/A Polymorphism and Cervical Cancer Risk: A Meta-Analysis.

Brehima Diakite1, Yaya Kassogue1, Mamoudou Maiga1,2,3, Guimogo Dolo1, Oumar Kassogue1, Jonah Musa2,3,4, Imran Morhason-Bello5, Ban Traore6, Cheick Bougadari Traore1, Bakarou Kamate1, Aissata Coulibaly1, Sekou Bah7, Sellama Nadifi8, Robert Murphy3, Jane L Holl9, Lifang Hou2,3.   

Abstract

A literature review showed some discrepancies regarding the association of -592C/A with the risk of cervical cancer. To allow more precise analysis of the data by increasing the number of cases studied and more acceptable generalization by considering results from different sources, the present meta-analysis was performed on available published studies that explored the relationship between SNP-592C/A of the IL-10 gene and the risk of cervical cancer. Eleven available studies, including 4187 cases and 3311 controls, were included in this study investigating the relationship between the -592C/A polymorphism of IL-10 and cervical cancer risk. Fixed-effects or random-effects models were performed with pooled odds ratios (ORs). Heterogeneity and bias tests were performed by the inconsistency test and funnel plot, respectively. The overall analysis showed an increased susceptibility to cervical cancer with the -592C/A polymorphism of the IL-10 gene for the recessive model (OR = 1.30, 95% CI = 1.14-1.49), dominant model (OR = 1.36, 95% CI = 1.09-1.70), and additive model (OR = 1.25, 95% CI = 1.09-1.44). Regarding ethnicity, a significant association of the -592C/A polymorphism of the IL-10 gene was linked to an elevated risk of cervical cancer for all genetic models (recessive, dominant, and additive) in the Asian populations and for the recessive and additive models in Caucasians with P < 0.05. The -592C/A polymorphism of the IL-10 gene may be considered a risk factor for cervical cancer.
Copyright © 2022 Brehima Diakite et al.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35919032      PMCID: PMC9296312          DOI: 10.1155/2022/2319161

Source DB:  PubMed          Journal:  Genet Res (Camb)        ISSN: 0016-6723            Impact factor:   1.375


1. Introduction

Cervical cancer is the fourth most common cancer in the world, accounting for 6.5% of all cancers, after breast, colorectal, and lung cancer. It is also the fourth highest cause of cancer death in women in both high-income and low-middle-income countries, with an estimated mortality rate of 7.7% worldwide (GLOBOCAN 2020) [1]. Exposure to high-risk human papillomavirus (HPV) is required but is not a sufficient cause of cervical cancer [2, 3]. Oncogenic HPV DNA is present in nearly 100% of invasive cervical cancers. A limited immune response to HPV linked to the host's genetic make-up may increase the risk of cervical cancer [4]. Many authors have been interested in the research of risk factors related to cervical cancer throughout the last few decades [5]. It appears from their investigations that genetic factors seem to exert a significant influence on the carcinogenesis of the cervix. Notably, the reported results are conflicting. However, mutations in genes involved in cytokine synthesis, such as interleukin 10 (IL-10), appear to be strong predictors of cervical cancer risk [6-8]. Physiologically, IL-10 is an essential cytokine for inflammatory modulation. Several cell types are involved in the production of this cytokine, including Th1, Th2, Th17 lymphocytes, B lymphocytes, mast cells, eosinophils, monocytes, macrophages, and dendritic cells [9, 10]. The IL-10 gene, which contains five exons, has been found on the long arm of chromosome 1q31-32 in humans [11, 12]. The significance of the IL-10 gene in the control of immune-mediated illness responses has resulted in the discovery of numerous polymorphisms in different portions of the gene, including the promoter region [4, 11]. The majority of identified genetic polymorphisms are single nucleotide polymorphisms (SNPs). The SNP-592C/A of the IL-10 gene promoter is located near a number of transcription factor binding sites. This SNP has been implicated in the pathogenesis of cutaneous malignant melanoma and prostate, breast, gastric, and cervical cancer [6, 13–18]. Association studies carried out in different populations have shown that this SNP increases the risk of developing cervical cancer [6, 17, 19]. However, other studies have reported conflicting results [7, 20, 21]. Furthermore, the expression of the IL-10 gene and/or the production of IL-10 has been demonstrated in various types of tumors, suggesting that IL-10 could, by promoting escape from the immune system, constitute a step in tumorigenesis [22-24]. Given the contradictory results of numerous studies on the role of SNP-592C/A of the IL-10 gene in the pathogenesis of cervical cancer, we conducted a meta-analysis to assess the association between SNP-592C/A in the IL-10 gene and the risk of cervical cancer.

2. Materials and Methods

2.1. Literature Search Strategy

The identification of initial manuscripts or published articles, available in English, was performed using the online databases PubMed, the Harvard University Library, Web of Science, and Genetics Medical Literature Database. Additional articles were identified from references cited in relevant reports and journals. The key search words “Interleukin-10” or “IL-10,” “−592C/A” or “−592C > A” or “rs1800872,” “polymorphism” or “variant” or “mutation” or “gene” or “cervical tumor” or “cervical cancer” were used to locate and select the articles.

2.2. Inclusion Criteria

The eligibility criteria were as follows: (1) case-control study design evaluating the association of the -592C/A polymorphisms of the IL-10 gene with the risk of cervical cancer, (2) availability of the full scientific manuscript, (3) distribution of polymorphisms in the controls in agreement with Hardy–Weinberg equilibrium (HWE), (4) availability of proportions of the different genotypes (CC, CA, AA for −592C/A of the IL-10 gene) in both cases and controls, and (5) no significant change in the value of the odds ratio (OR).

2.3. Data Extraction

Three authors independently carried out the literature search to optimize the convergence of the retrieved data, including principal author, year of publication, study design, study population, racial and ethnic groups, sample size, genotypic and allelic proportions in cases and controls, HWE calculation, and genetic models tested.

2.4. Statistical Analysis

The statistical analyses were conducted using Review Manager v5.3 and MedCalc v14.8.1. The distribution of the −592C/A polymorphism of the IL-10 gene in agreement with HWE in the controls was evaluated by a chi-square test, with P < 0.05. A pooled OR test with a 95% confidence interval (CI) was used to assess the strength of the association between the −592C/A polymorphism in the IL-10 gene and the risk of cervical cancer, including the recessive model (AA vs. CC + CA), the dominant model (AA + CA vs. CC), and the additive model (A vs. C). To avoid type I error, the level of significance was corrected using Bonferroni's adjustment during multiple comparisons. An inconsistency (I2) statistical test was used to determine heterogeneity [25, 26]. If there was no heterogeneity (I2 < 50%), a fixed-effect model (FEM) was retained for interpretation of a global OR. In the case of heterogeneity, the OR was interpreted using a random-effect model (REM). A funnel plot was used to determine bias [27]. The trial sequential analysis (TSA) software was used to estimate the sample size required for each arm to assess the robustness of the meta-analysis findings with 90% statistical power [28].

3. Results

3.1. Characteristics of Eligible Studies

Four Caucasian studies with 2221 cases and 1240 controls [17, 21, 29, 30] and seven Asian studies with 1966 cases and 2071 controls [6, 7, 20, 31–34] were eligible to conduct the current meta-analysis out of thirteen studies (Figure 1) (Table 1). Only one study on Africans was found, and it was discarded due to Hardy–Weinberg's imbalance [8]. Another study that had a major impact on the overall OR was also excluded [19].
Figure 1

Flow diagram of eligible studies included.

Table 1

Genotypic distribution of the IL-10-592C/A polymorphism in eligible studies.

Author/yearRace/ethnicityCasesControls
N CC CA AA N CC CA AA HWE
[20]Asian1652082631651580700.24
[6]Asian240491335820465111280.07
[7]Asian104438052214211004585201220.15
[29]Caucasian128273646482288162112140.33
[21]Caucasian852450111466862160.74
[31]Asian1441156771791577870.72
[32]Asian20016968820017102810.05
[17]Caucasian2004498582008585300.25
[33]Asian701223351081344510.46
[34]Asian103737591151944520.07
[30]Caucasian65439323130606405175260.20

N: number.

3.2. Quantitative Analysis

Table 2 denotes the association between cervical cancer and SNP-592C/A of IL-10 for the genetic models. Overall, a significant association was found between the risk of cervical cancer and the three genetic models, including the recessive (OR (FEM) = 1.30, 95% CI = 1.14–1.49, P=0.0001), dominant (OR (REM) = 1.36, 95% CI = 1.09–1.70, P=0.006), and additive models (OR (REM) = 1.25, 95% CI = 1.09–1.44, P=0.001) (Figure 2).
Table 2

Genetic models and SNP-592C/A in the IL-10 gene in cervical cancer.

Study N Cases/controlModelsEffect estimate/statisticalBonferroniHeterogeneity
OR (95% CI) P value α Sig I 2 (%) P
All studies114187/3311
Recessive1.30 (1.14–1.49)0.00010.016Yes280.18
Dominant1.36 (1.09–1.70)∗∗0.0060.016Yes66<0.05
Additive1.25 (1.09–1.44)∗∗0.0010.025Yes66<0.05

Caucasian42221/1240
Recessive1.50 (1.12–2.00)0.0060.016Yes390.18
Dominant1.57 (1.03–2.40)∗∗0.040.016No84<0.05
Additive1.15 (1.15–1.46)∗∗<0.00010.025Yes81<0.05

Asian71966/2071
Recessive1.25 (1.07–1.46)0.0040.016Yes240.25
Dominant1.26 (1.09–1.46)0.0020.016Yes420.11
Additive1.19 (1.08–1.30)0.00020.035Yes500.06

N: number; P: P value OR; P′: P value of heterogeneity; I2: inconsistency; recessive model: AA vs. CC + CA; dominant model: AA + CA vs. CC; additive model: A vs. C;  = fixed-effect model,  = random-effect model; N = number; α = Bonferroni correction; Sig = Bonferroni significance.

Figure 2

Forest plots of the association between the -592C/A polymorphism of the IL-10 gene and cervical cancer for the (a) recessive model, (b) dominant model, and (c) additive model. The pooled OR is represented by a black diamond, the OR in each study is represented by blue squares with square sizes inversely proportionate to the standard error of the OR, and the horizontal lines represent the 95% CI.

Based on analysis by race/ethnicity (Table 2), the -592C/A polymorphism of the IL-10 gene was significantly associated with an increased risk of cervical cancer in Caucasians for the recessive model (OR (FEM) = 1.50, 95% CI = 1.12–2.00, p=0.006), dominant model (OR (REM) = 1.57, 95% CI = 1.03–2.40, P=0.04), and additive model (OR (FEM) = 1.15, 95% CI = 1.15–1.46, P < 0.0001) (Figure 3). Furthermore, an association of this polymorphism with cervical cancer was observed in the Asian populations for the recessive (OR (FEM) = 1.25, 95% CI = 1.07–1.46, P=0.004), dominant (OR (FEM) = 1.26, 95% CI = 1.09–1.46, P=0.002), and additive (OR (FEM) = 1.19, 95% CI = 1.08–1.30, P=0.0002) models (Figure 4). After Bonferroni correction adjusts P value, a nonsignificant association was found between IL-10 -592C/A polymorphism and cancer for the dominant model in Caucasians.
Figure 3

Forest plots of the association between SNP-592C/A in the IL-10 gene and cervical cancer for the (a) recessive model, (b) dominant model, and (c) additive model in the Caucasian population. The pooled OR is represented by a black diamond, the OR in each study is represented by blue squares with square sizes inversely proportionate to the standard error of the OR, and the horizontal lines represent the 95% CI.

Figure 4

Forest plots of the association between the -592C/A polymorphism of the IL-10 gene and cervical cancer for the (a) recessive model, (b) dominant model, and (c) additive model in the Asian population. The black diamond represents the pooled OR, the blue squares show the OR in each study with square sizes inversely proportional to the standard error of the OR, and the horizontal lines denote the 95% CI.

3.3. Sensitivity Analysis

The stability of the meta-analysis was maintained by removing studies that significantly changed the overall OR and P value after excluding those that deviated from HWE [8]. In this regard, only the article by Singhal et al. has been omitted [19].

3.4. Heterogeneity Source

We found heterogeneity for the dominant and additive models with I2 > 50 and I2 = 66 percent, respectively, when we excluded studies that deviated from HWE and the ones that significantly affected the cumulative OR value (Figures 2(b) and 2(c)). The genetic models showed no heterogeneity in the race/ethnicity study, except for the dominating pattern in Caucasians (I2 = 84 percent, P=0.0003) (Figure 3(b)).

3.5. Publication Bias

The evaluation of publication bias was conducted by performing funnel plots. An absence of publication bias was observed for the recessive, dominant, and additive models after removing studies, not in agreement with the HWE and the study modifying the value of the pooled OR (Figure 5).
Figure 5

Funnel plots of the (a) recessive model, (b) dominant model, and (c) additive model precision by OR.

4. Results of TSA

The TSA's outcome is depicted in Figure 6. The conclusions of the present meta-analysis are strong because the required sample size is 3669 and the cumulative z-curve reached the requested sample size by crossing the upper limit of sequential trial monitoring.
Figure 6

Trial sequential analysis for IL10-592C/A polymorphism under the genotype contrast model. The x-axis shows the number of participants (cases and controls) of the meta-analysis in each branch. The y-axis z-score shows the z-score. The red line represents the required sample size. The green line represents the conventional test boundary (P=0.05).

5. Discussion

HPV infection is one of the leading causes of cervical cancer, yet it is not sufficient to trigger cervical carcinogenesis. Smoking, HIV, fetal exposure to diethylstilbestrol, and oral contraceptives have all been identified as additional risk factors. Although genetic variables have been linked to carcinogenesis, the mechanism by which the IL-10 gene polymorphism causes cervical cancer is unknown. In vitro, IL-10 has been shown to have powerful immunosuppressive and antiinflammatory activities [35-37]. This cytokine is produced by a variety of cell types, such as CD4 T cells and monocytes/macrophages [38, 39]. Macrophages' ability to present antigens to T cells, as well as their ability to provide a costimulatory signal to T cells, is reduced by IL-10. It performs this function by inhibiting the activation of class II MHC-11 molecules and specific accessory molecules on their surfaces, including the B7.1 molecule [40]. By blocking cell-mediated immune responses and inflammatory reactions, IL-10 can promote carcinogenesis by limiting the development of an adequate antitumor response against tumor cells [40, 41]. It is worth noting that, in addition to its inhibitory characteristics, IL-10 stimulates antibody production, as well as the differentiation and proliferation of B lymphocytes, which in turn produce IL-10 [42-44]. Furthermore, the expression of the IL-10 gene has been confirmed in various tumors, suggesting that IL-10 could play a nonnegligible role in carcinogenesis by allowing the immune system to escape [4]. In promoter regions, functional polymorphisms of the IL-10 gene such as -592C/A can lead to changes in the affinity of transcriptional factors, thereby altering levels of mRNA expression (dose-dependent effect) of inflammatory cytokines associated with the occurrence of cancer [22, 45]. In the present study, including 4187 cases and 3311 controls, we noted that the −592C/A polymorphism of the IL-10 gene was correlated with the overall risk of cervical cancer for the recessive, dominant, and additive models. This finding is in line with a previous meta-analysis that identified a significant association between the −592C/A polymorphism and an increased risk of cervical cancer in 2396 cases and 1388 controls [46]. Contrary to our results, Guo et al. reported in a meta-analysis of 3,149 cases and 2,237 controls that the −592C/A polymorphism was not globally correlated with cervical cancer for the three genetic models [14]. A recent meta-analysis with 1,393 cases and 1,307 controls also found conflicting results [47]. In Caucasians and Asians, our meta-analysis adjusted for race and ethnicity found an association between the −592C/A polymorphism and cervical cancer in all models. Some meta-analyses supported our conclusions in some respects. This was the case in the meta-analysis by Guo et al. on the Caucasian population, which found that only the recessive model was associated with an increased risk of cervical cancer [14], and another meta-analysis from the Asian population, which found that the additive model was associated with the risk of cervical cancer [46]. However, Wang et al. found that the −592C/A polymorphism had no effect on the risk of cervical cancer in Caucasian and Asian populations across all genetic models tested [47]. Furthermore, Torres-Poveda et al. and Pereira et al. found a correlation between the −592C/A polymorphism and cervical cancer in the Mexican and Brazilian populations for all three models, respectively [17, 21]. Zoodsma et al., Du et al., and Datta et al. reported that the risk of cervical cancer was correlated with the −592C/A SNP in the IL-10 gene for the dominant and additive models in Netherlander, Chinese, and Bangladeshi populations, respectively [6, 7, 30]. These discrepancies between studies can be explained by a few factors, including (1) sample size differences between studies, (2) inclusion of studies with allele frequencies that deviate from the HWE, (3) inclusion of studies that change the pooled OR value, (4) population genetic background, and (5) inclusion of studies based on noncancerous cervical lesions [8, 19, 48]. The present study shows certain limitations as follows: the limited number of case and control studies carried out on the association of SNP-592C/A in the IL-10 gene with the risk of cervical cancer, particularly in the Caucasian and African populations (almost absent), and the sample size. Although the sample size requirement showed statistical power of 90%, a more representative sample size from different populations worldwide could confirm or refute a robust conclusion.

6. Conclusions

Based on an analysis of a large sample with precise inclusion criteria, this study reveals that women with the −529C/A polymorphism of the IL-10 gene promoter have a high risk of cervical cancer for genetic models and provides evidence of an association of the IL-10 gene promoter in the pathogenesis of cervical cancer.

7. Disclosure

This manuscript was presented as a preprint in “Association of Interleukin-10 −592C/A Polymorphism and Cervical Cancer Risk: A Meta-Analysis” (Preprint) [49]
  44 in total

1.  Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease.

Authors:  M Zoodsma; I M Nolte; M Schipper; E Oosterom; G van der Steege; E G E de Vries; G J Te Meerman; A G J van der Zee
Journal:  Int J Gynecol Cancer       Date:  2005 Nov-Dec       Impact factor: 3.437

2.  Association study of IL10 gene polymorphisms (rs1800872 and rs1800896) with cervical cancer in the Bangladeshi women.

Authors:  Anamika Datta; Fatema Tuz Zahora; Md Abdul Aziz; Mohammad Sarowar Uddin; Mahmuda Ferdous; Md Shalahuddin Millat; Md Shahid Sarwar; Md Abdul Barek; Sarah Jafrin; Shamsun Nahar; Mohammad Safiqul Islam
Journal:  Int Immunopharmacol       Date:  2020-10-16       Impact factor: 4.932

3.  IL-10 c.-592C>A (rs1800872) polymorphism is associated with cervical cancer.

Authors:  Ana Paula Lombardi Pereira; Kleber Paiva Trugilo; Nádia Calvo Martins Okuyama; Michelle Mota Sena; José D'Oliveira Couto-Filho; Maria Angelica Ehara Watanabe; Karen Brajão de Oliveira
Journal:  J Cancer Res Clin Oncol       Date:  2020-05-23       Impact factor: 4.553

4.  IL-10 gene promoter and intron polymorphisms as genetic biomarkers of cervical cancer susceptibility among Tunisians.

Authors:  Sabrina Zidi; Ezzedine Gazouani; Mouna Stayoussef; Amel Mezlini; Salma K Ahmed; Besma Yacoubi-Loueslati; Wassim Y Almawi
Journal:  Cytokine       Date:  2015-06-12       Impact factor: 3.861

5.  Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10.

Authors:  Jason S Stumhofer; Jonathan S Silver; Arian Laurence; Paige M Porrett; Tajie H Harris; Laurence A Turka; Matthias Ernst; Christiaan J M Saris; John J O'Shea; Christopher A Hunter
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

6.  Genetic polymorphisms in tumor necrosis factor alpha and interleukin-10 are associated with an increased risk of cervical cancer.

Authors:  Guang-Hui Du; Jun-Kang Wang; Jackson R Richards; Jia-Jia Wang
Journal:  Int Immunopharmacol       Date:  2018-11-16       Impact factor: 4.932

Review 7.  Immunosuppressive and anti-inflammatory properties of interleukin 10.

Authors:  J E de Vries
Journal:  Ann Med       Date:  1995-10       Impact factor: 4.709

8.  Involvement of interleukin-10 promoter polymorphisms in nonmelanoma skin cancers-a case study in non-Caucasian skin cancer patients.

Authors:  Tohru Nagano; Makoto Kunisada; Xijun Yu; Taro Masaki; Chikako Nishigori
Journal:  Photochem Photobiol       Date:  2008 Jan-Feb       Impact factor: 3.421

9.  Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer.

Authors:  Emma L Ivansson; Inger M Gustavsson; Jessica J Magnusson; Lori L Steiner; Patrik K E Magnusson; Henry A Erlich; Ulf B Gyllensten
Journal:  Int J Cancer       Date:  2007-12-01       Impact factor: 7.396

10.  Genetic Polymorphisms in IL-10 Promoter Are Associated With Smoking and Prostate Cancer Risk in African Americans.

Authors:  Muneer Abbas; Tshela Mason; Aliza Ibad; Mozna Khraiwesh; Victor Apprey; Yasmine Kanaan; Bradford Wilson; Georgia Dunston; Luisel Ricks-Santi; Hassan Brim
Journal:  Anticancer Res       Date:  2020-01       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.